43 results about "Mannose receptor" patented technology

The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.

The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.

The invention discloses a preparation method of a targeted nano vaccine based on a metal-polyphenol network structure. The preparation method comprises the following steps that mesoporous silica nanoparticles loaded with ovalbumin OVA are prepared, mannose-modified tannic acid molecules are synthesized, and the surfaces of the mesoporous silica nanoparticles loaded with the ovalbumin OVA are coated with metal-polyphenol network coatings, so that the mesoporous silica nanoparticles loaded with the OVA and with the surfaces coated with the metal-polyphenol network coatings are obtained, therefore the targeted nano-vaccine based on the metal-polyphenol network structures is obtained, and the targeted nano-vaccine is named as MS@OVA@MPN@Man. According to the preparation method, the surfaces are coated with the metal-polyphenol network coatings, so that leakage of OVA is prevented, and the lysosome escape function of the nanoparticles is increased; and meanwhile, mannose is modified on thesurface to target a mannose receptor on the surface of an immune cell, so that the uptake capacity of the cell to the mannose receptor is enhanced to improve the vaccine delivery efficiency, and the problems of targeting of the nano vaccine and lysosome escape efficiency are solved.

The invention belongs to the fields of pharmaceutical preparations and drug delivery of gene vaccine carriers and particularly relates to a dendritic cell-targeted pH-response type DNA vaccine delivery system and a preparation method thereof. According to the delivery system, second-generation lysine substituted distearoyl Phosphoethanolamine (DSPE-G2) is taken as a DNA carrier material, citraconoyl polyacrylamide (PAH-Cit) is taken as a pH-sensitive charge reversion material, mannosylated chitosan (MCS) is taken as a dendritic cell-targeted material, and the materials are organically combined in a layer-by-layer self-assembling manner to form a quaternary compound as the DNA vaccine delivery system, so that the procedural transfection of the DNA vaccine to dendritic cells is realized, and the transfection efficiency is improved. According to the dendritic cell-targeted pH-response type DNA vaccine delivery system, stable composite nanoparticles can be formed to specifically target a specific targete mannose acceptors on the surfaces of the dendritic cells so as to generate charge reversion under a weak acid environment in an endosome-lysosome system, so that the structures of the composite nanoparticles are broken, the release of DNA is promoted, and finally the gene transfection efficiency is remarkably improved. The dendritic cell-targeted pH-response type DNA vaccine delivery system has great utilization potentiality.

The invention relates to medical contrast agents, and particularly relates to a vital staining contrast agent by using polyuronide as a vector, as well as a preparation method and an application thereof. A macromolecular contrast agent with excellent water solubility is prepared by using polyuronide as the vector, mannose or mannose derivatives as a mannose receptor (MBP) recognition group and a paramagnetic metal ion chelate as a magnetic resonance imaging group, the lymphoid tissue binding force is improved, and the aim of binding mannose or mannose derivative group which is introduced into the synthesized contrast agent molecules with the mannose receptor enriched in the lymphoid tissues can be achieved. Furthermore, preoperative lymph imaging mapping is beneficial to intraoperative sentinel lymph node mapping and lymph node cleaning operation in a delicate tumor surgical operating process, and can be widely applied to breast cancer, head and neck cancer, melanotic cancer and other preoperative sentinel lymph node mappings. The contrast agent can be used for simultaneously meeting the requirement for biopsy and magnetic resonance imaging, and is an excellent difunctional lymph target contrast agent.

The invention discloses novel medicinal application of baicalein, in particular to application of the baicalein to the preparation of medicament for treating demyelinative diseases of central nervous system. The baicalein shows favorable treatment functions on an experimental allergic cerebrospinal meningitis model of a mouse and the treatment functions are achieved by inhibiting microglia 12/15 lipoxygenase in the central nervous system and adjusting the expression condition of a group of molecules with nerve protecting functions, such as FIZZ1 (foundininflammatoryzone1), MRC1 (mannose receptor, C type 1) and Arg1 (arginase 1) on the mRNA (messenger ribonucleic acid) level, thereby inducing high-level M2 type microglia in the central nervous system. The M2 type microglia has the function of CNS (central nervous system) neuroendocrine nutrilit and can promote the repair of medullary sheath, thereby relieving the progress of disease conditions.

The invention discloses a preparation method of a cell strain capable of expressing glucocerebrosidase with high mannose content. The preparation method comprises the following steps: (1) carrying outlipofection transfection, namely, aiming at the sequence of a GNT1 gene, designing a sgRNA sequence guiding cutting of endonuclease, recombining the sgRNA sequence into a knock-out vector, thus obtaining synthetic plasmids with coexpression of sgRNA and endonuclease, and transfecting a cell pool stably expressing glucocerebrosidase by adopting the synthetic plasmids through a liposome transfection method; (2) carrying out cloning by adopting a limiting dilution method, namely, screening out monoclonal cells, and carrying out enlarged culturing; (3) carrying out mutation cloning screening on the target gene, namely, acquiring monoclone with the GNT1 gene knocked out through cell PCR sequencing, and thus the cell strain capable of expressing glucocerebrosidase with high mannose content is obtained. The cell strain can stably express glucocerebrosidase, meanwhile, the content of the mannose is obviously improved, the binding capacity with mannose receptor is effectively improved, the enzyme activity capacity is improved, and the purpose of increasing the efficacies is achieved.

The invention belongs to the technical field of medicines, and particularly relates to a targeting element with a targeting function and a preparation method thereof, a method for improving the drug delivery capacity of a targeting carrier, a method for improving the transfection efficiency of a transfection reagent, a compound, a targeting oil phase and a water phase. The targeting element is composed of a targeting material and a spacing material, and the targeting material is mannose and/or a mannose derivative. The targeting element and the targeting carrier can well target a mannose receptor, and can be efficiently combined with the mannose receptor on a target cell; the preparation cost is low, the synthesis is easy, the universality is realized, various targeting nano preparations can be synthesized, and the purification and characterization are facilitated; and the targeting element can be used for improving the transfection efficiency of the transfection reagent and applied toscientific research and business.

The invention discloses a genetic vector material, and a preparation method and application thereof. The genetic vector material is a polymer formed by polysaccharide 6-hydroxyl grafted polyamine. The method comprise the steps of (1) acylating polysaccharide with an acylation reagent to prepare an acylation intermediate, and (2) allowing the acylation intermediate to react with polyamine, so as to obtain the genetic vector material. The invention further discloses the application of the genetic vector material in a gene preparation transfection system. The genetic vector material can be subjected to specific recognition by mannose receptor on a cell surface, and has good liver targeting, low toxicity, higher gene transfection efficiency, and good research and application prospects in in-vivo/vitro transfection of the receptor.

The invention relates to a nano suspension for oral protein immunization and a preparation method thereof, and belongs to the field of medicine. Bovine serum albumin (BSA) is taken as the model drug, PLGA is taken as the carrier, and a solvent volatilization method is adopted to prepare a BSA loaded MCS/PLGA/BSA nano suspension. The particle size of the suspension is 532.8 nm, the zeta potential is 28.92 mv, and the encapsulation rate is 89.34%. Mannosylated chitosan (MCS) is adsorbed on the surface of PLGA/BSA nano particles through a static effect, thus the stability of nano particles in gastrointestinal liquid becomes more stable, moreover, the stay time in intestinal cavity is prolonged, and the nano particles with positive charges can be absorbed by cells more easily. Nano particles are transferred by epithelium related with follicle to PP nodes; through the combination between mannose ligands and mannose acceptors on antigen-presenting cells (APCs), the intake of APCs is increased, and thus the immunization reactions are induced.

Disclosed is a lymph targeting nuclear magnetic contrast agent using a brown algae polysaccharide as a carrier, and a preparation method and a use thereof. A macromolecular contrast agent with good water solubility was prepared by using the brown algae polysaccharide as the carrier, using mannose or mannose derivatives as a mannose receptor (MBP) recognition group, and using a paramagnetic metal ion chelate as a nuclear magnetic resonance imaging group. The binding capacity of lymphoid tissue was improved. The mannose or mannose derivative group introduced into the synthesized contrast agent molecule achieves the goal of binding to the enriched mannose receptors in the lymphoid tissues. At the same time, after the contrast agent is injected subcutaneously, both lymph vessels and lymph nodes were clearly visualized under MRI scanning The intensification rate and enhancement time of the lymph node signal at one side of the animal body injected with the contrast agent was significantly enhanced, so as to achieve a clear mapping and precise positioning of the lymph nodes and the lymph vessels. It is of great significance for the detection and diagnosis of lymph system diseases.

The invention belongs to the field of medicinal preparations, and particularly relates to a composition of a nanometer preparation having a targeting function, a targeting carrier and a preparation method thereof, a targeting medicine and a method for improving targeting properties of the targeting carrier. The composition of the nanometer preparation having a targeting function consists of a targeting material, a basic nanometer preparation material, and an interval material enabling the targeting material and the basic nanometer preparation material to produce distances. The targeting nanometer preparation has better mannose receptor targeting properties and can be efficiently combined with a mannose receptor on a target cell; and besides, the preparation method has generality, various targeting nanometer preparations can be synthesized, and purification and representation are facilitated.

The present invention provides novel antibody vaccine conjugates and methods of using them to induce cytotoxic T cell (CTL) responses. In a specific embodiment, the vaccine conjugate comprises human chorionic gonadotropin beta subunit (beta hCG) antigen linked to an anti-mannose receptor (MR) antibody.

The invention discloses a targeting carrier suitable for anti-African swine fever virus siRNA drugs. The targeting carrier comprises a polyvalent carbohydrate chain and a linker, wherein a carbohydrate unit at the tail end of the carbohydrate chain is D-mannose that can be recognized by a mannose receptor; the linker is used for connecting the polyvalent carbohydrate chain and the anti-African swine fever virus siRNA drug, and at least one carboxyl group and at least one hydroxy group are arranged at the tail end of the linker, and are correspondingly used for connecting the polyvalent carbohydrate chain and the anti-African swine fever virus siRNA drug. The targeting carrier provided by the invention is a novel mannose receptor carrier, can be combined with the siRNA drug special for resisting African swine fever viruses, recognize the mannose receptors of macrophage or dendritic cells in a targeted mode, and enters the cells through endocytosis, so that the treatment effect of the drug is improved and toxic and side effects on other tissues are reduced, the targeting effect is strong, and the safety is high. In the cells, the siRNA drug can inhibit the expression of a target gene, so that the target gene is silent, and thus the purpose of killing the viruses is achieved.

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.